Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.
Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM, Assouline SE, Balitsky A, Fraser GA, Mangel J, Owen C, Reiman A, Sehn LH, Sutherland HJ, Arnold C, McCurdy A, Reece D, Leite T, McCarthy E, Cooper C, Crawley A, Langlois MA, Buchan CA.
Bhella S, et al. Among authors: arnold c.
Blood Adv. 2026 Jan 27:bloodadvances.2025018117. doi: 10.1182/bloodadvances.2025018117. Online ahead of print.
Blood Adv. 2026.
PMID: 41592280